Intraductal Papilloma Market Overview
The Intraductal Papilloma Market is expected to reach USD 6020.2 Million by 2030 at 4.10% CAGR during the forecast period 2022-2030. An intraductal papilloma is a benign, or noncancerous, breast tumour that forms in a milk duct and is made of gland and fibrous tissue as well as blood vessels. These generally appear as lumps after breast examination and may cause nipple discharge or bleeding. Intraductal papilloma most commonly occur in women between ages 35 and 55. Central/solitary papillomas are generally benign while multiple papillomas, have been associated with a slightly higher risk of breast cancer.
The symptoms of intraductal papilloma are breast enlargement, inversion of the nipple, thickening or swelling of part of the breast, changes to the breast or nipple skin area, such as dimpling, redness, scaling, peeling etc. Multiple papillomas consist of about 10 % of all intraductal papillomas. Intraductal papilloma comprise approximately 10% of all benign breast tumour types and are benign lesions with an incidence of approximately 2-3% in humans. Risk factors such as obesity, alcohol consumption, postmenopausal hormone therapy, having the first child after the age of 35, or never having a child, medications containing estrogen and progesterone such as birth control pills, menstrual cycle abnormalities, physical inactivity, not breastfeeding the child etc. increase the chances of intraductal papillomas.
The market for intraductal papilloma Market is constrained by the lack of awareness, high cost of surgery, complications of the surgery, lack of focus on women health in the developing and poorer regions of the world etc. Market development represents the best strategy for the market growth. The market will witness exponential growth over the review period owing to minimal invasive surgeries procedures such as needle aspiration biopsy surgeries etc.
Research Methodology
Sources: Mayo Clinic, Healthline Media, MRFR Analysis
Intended Audience
- Global intraductal papilloma treatment manufacturers & suppliers
- Research and development (R&D) companies
- Hospitals and clinics
- Academic institutes and universities
Figure 1 Global Intraductal Papilloma Market by Type, 2016 (%)
Global Intraductal Papilloma Market Segmentation
The intraductal papilloma market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on type, the Intraductal papilloma Market has been segmented as central/solitary papillomas, peripheral/multiple papillomas and others.
Based on diagnosis, the market has been segmented as examination, ultrasonography, biopsy, mammogram/galactography, ductograms, Computerized Tomography (CT) and others.
Based on surgery, the market has been segmented as microdochectomy, total duct excision, drugs and others.
Based on the end user, Intraductal papilloma Market has been segmented as hospitals & clinics, academic and research, and others.
Global Intraductal Papilloma Market Regional Analysis
The Americas account for a significant market share owing to extensive volume of surgeries performed and high expenditure on the health care. Additionally, the fastest uptake of new products and surgical procedures in the US drive the intraductal papilloma market. Also, concentration of major healthcare companies in the developed countries of this region coupled with the larger insurance penetration is adding fuel to Intraductal papilloma Market growth. Moreover, the US spends high on its healthcare, which accounts for 16% of GDP, further cruising the market for intraductal papilloma treatment.
Europe is the second largest market in the world due to high income and strong healthcare penetration. European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs during the forecast period. South East Asian countries such as Vietnam, Thailand, and Malaysia are projected to contribute highly to the market growth.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for will be Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.
Key Players in the Intraductal papilloma Market
Some of key players profiled in the report are:
- Allergen plc
- Teva Pharmaceutical Industries Ltd.
- Mylan Pharmaceuticals Inc.
- Entax Medical
- Olympus
- Boston Scientific Corporation
- Medtronic
- Cook Medical, Inc.
Report Attribute/Metric |
Details |
Market Size |
  USD 6020.2 Million |
CAGR |
  4.10% (2022-2030) |
Base Year |
  2021 |
Forecast Period |
  2022-2030 |
Historical Data |
  2020 |
Forecast Units |
 Value (USD Million) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered |
Type, Diagnosis, Treatment, and End User |
Geographies Covered |
America, Europe, Asia Pacific, Middle East and Africa |
Key Vendors |
Allergen plc, Teva Pharmaceutical Industries Ltd., Mylan Pharmaceuticals Inc., Entax Medical, Olympus, Boston Scientific Corporation, Medtronic, Cook Medical, Cook Medical, Inc., and others |
Key Market Opportunities |
Minimal invasive surgeries procedures |
Key Market Drivers |
Risk factors such as obesity, alcohol consumption, postmenopausal hormone therapy, medications containing estrogen and progesterone |
Intraductal Papilloma Market Highlights:
Frequently Asked Questions (FAQ) :
Intraductal Papilloma Market valuation would be USD 6020.2 Million by 2030.
Intraductal Papilloma Market CAGR would be 4.10% during the forecast period.
The Americas would dominate the Intraductal Papilloma Market.
The fastest-growing Intraductal Papilloma Market in Europe would be the UK.
The Intraductal Papilloma Market players would be Teva Pharmaceutical Industries Ltd., Allergen plc, Entax Medical, Mylan Pharmaceuticals Inc., Boston Scientific Corporation, Cook Medical, Inc., Medtronic, Cook Medical, Olympus, and others.